Assertio Increases Full-Year Net Product Sales Outlook to in Excess of $152 Million
05 December 2022 - 11:30PM
Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq:
ASRT), a specialty pharmaceutical company offering differentiated
products to patients, today announced that it is raising its
outlook for 2022 full-year net product sales to greater than $152
million, increased from its prior outlook calling for net product
sales of greater than $141 million for the full year. The Company
noted that net product sales to date in the fourth quarter have
significantly exceeded its prior expectations used in formulating
the Company’s outlook provided with its third quarter results on
November 8, 2022.
Said Dan Peisert, President and Chief Executive Officer of
Assertio, “Net product sales in 2022 have consistently exceeded
expectations. The revised outlook is driven by better than
anticipated volume across the majority of our portfolio, and
particularly Indocin. Our recent addition of Sympazan is also
generating higher sales than our original projections.”
About Assertio
Assertio is a specialty pharmaceutical company offering
differentiated products to patients utilizing a non-personal
promotional model. We have built and continue to build our
commercial portfolio by identifying new opportunities within our
existing products as well as acquisitions or licensing of
additional approved products. To learn more about Assertio, visit
www.assertiotx.com.
Investor Contact
Matt KrepsManaging DirectorDarrow AssociatesM:
214-597-8200mkreps@darrowir.com
Forward Looking Statements
Statements in this communication that are not historical facts
are forward-looking statements that reflect Assertio's current
expectations, assumptions and estimates of future performance and
economic conditions. These forward-looking statements are made in
reliance on the safe harbor provisions of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. These forward-looking
statements relate to, among other things, future events or the
future performance or operations of Assertio, including our ability
to realize the benefits from our operating model, successfully
acquire and integrate new assets and explore new business
development initiatives. All statements other than historical facts
may be forward-looking statements and can be identified by words
such as "anticipate," "believe," "could," "design," "estimate,"
"expect," "forecast," "goal," "guidance," "imply," "intend," "may",
"objective," "opportunity," "outlook," "plan," "position,"
"potential," "predict," "project," "prospective," "pursue," "seek,"
"should," "strategy," "target," "would," "will," "aim" or other
similar expressions that convey the uncertainty of future events or
outcomes and are used to identify forward-looking statements. Such
forward-looking statements are not guarantees of future performance
and are subject to risks, uncertainties and other factors, some of
which are beyond the control of Assertio, including the risks
described in Assertio's Annual Report on Form 10-K and Quarterly
Reports on Form 10-Q filed with the U.S. Securities and Exchange
Commission ("SEC") and in other filings Assertio makes with the SEC
from time to time. Investors and potential investors are urged not
to place undue reliance on forward-looking statements in this
communication, which speak only as of this date. While Assertio may
elect to update these forward-looking statements at some point in
the future, it specifically disclaims any obligation to update or
revise any forward-looking-statements contained in this press
release whether as a result of new information or future events,
except as may be required by applicable law. Nothing contained
herein constitutes or will be deemed to constitute a forecast,
projection or estimate of the future financial performance or
expected results of Assertio.
Assertio (NASDAQ:ASRT)
Historical Stock Chart
From Oct 2023 to Dec 2023
Assertio (NASDAQ:ASRT)
Historical Stock Chart
From Dec 2022 to Dec 2023